We are privately inviting existing investors and new friends to invest first, with preferred terms. This is only available to accredited investors.

If you'd like to explore an investment of $5,000 or more, I'm happy to schedule a call with you. Please reach out to me directly at [email protected].

If you are not accredited, or would like to invest less than $5,000, we are planning to open up a Community Round in August for everyone to participate in our future growth, and we look forward to welcoming you.

Thank you!

We Make the Invisible Actionable

Our bodies are constantly communicating. Every breath, every movement, every recovery attempt leaves signals behind. Those signals are often present weeks before a crisis. Healthcare simply has not had a practical way to listen.

We are driven by a simple idea: the future of healthcare belongs to systems that continuously understand how people are breathing, moving, and recovering. Not during an annual checkup. Every day.

We started in respiratory disease because the need was urgent and personal. Our CEO Sharon Samjitsingh has lived with asthma her entire life, done everything right, and still nearly died five times. That experience drives every product decision we make.

Respiratory affects more than 600 million people worldwide. But respiratory was never the category. Physical AI in chronic disease management is. Long before that term entered the mainstream conversation, we were already building it.

We're now growing and demonstrating the proof. Our acquisition of Imago Rehab expanded the platform into stroke recovery, neurorehabilitation, and speech therapy. Different conditions, but the same fundamental challenge: getting people the right support at the right moment, before a crisis occurs.

HCO owns the entire feedback loop. We capture the signals. We build the intelligence that interprets them. We deliver the care that responds. Every interaction makes the platform smarter. Each new disease category we enter costs a fraction of the last.

We call it making the invisible actionable. It's one of the largest uncaptured opportunities in healthcare, and we are already capturing it.

LTV: Lifetime Value; CAC: Cost of Customer Acquisition; NPS: Net Promoter Score

The graphic above tells part of the story. Here is the rest.

In Respiratory, we have signed contracts covering 400,000 lives. We were exclusively chosen by the Asthma and Allergy Foundation of America for their HEAL program. Two additional health plans are in active evaluation representing $129M in avoidable spend.

In Neuro, we acquired Imago Rehab and turned it around completely. In five months: 3X revenue growth, 76% CAC reduction, first positive contribution margin in the business's five-year history. NPS is 95. We are waitlisted in most states.

We are no longer asking whether this approach can work. We are focused on how far it can go.

One Platform. 3 Layers.

For generations, physicians were trained to learn from the body itself. They listened to heart sounds, lung sounds, pulse points, and vibrations. Those signals often provided the earliest clues that something was changing. The problem was never that the signals lacked value. The problem was scale.

A physician can only listen occasionally. A patient lives with their condition every day.

Our co-founder Jared, named on all our patents, has often said he wants our technology to become as ubiquitous as the household thermometer. Not because it diagnoses disease on its own, but because it transforms something previously subjective into something measurable and actionable. A thermometer became indispensable for exactly that reason. We believe the same opportunity exists across a much broader range of physiological signals.

Respiratory was the first application. The platform has always been the objective.

Signals

Our proprietary technologies capture physiological signals that are often invisible to patients, clinicians, and traditional monitoring systems. ADAMM continuously listens to the lungs and airways. In neurorehabilitation, our soft robotic systems capture movement, effort, and recovery progress in the home. These signals create a continuous picture of what is actually happening inside the body, rather than relying on occasional clinic visits or patient recollection.

Intelligence

Those signals feed Aidah, our AI intelligence layer. Aidah is built on the idea that every individual has a unique physiological baseline, and that meaningful deterioration often appears first as subtle changes rather than dramatic events. Aidah continuously builds a living model of each person, identifying patterns, predicting risk, and determining which interventions are most likely to help.

Care

Insight must become action. The final layer is care itself, delivered through respiratory therapists, occupational therapists, physical therapists, and speech therapists, and increasingly through AI-powered support that extends their reach. Every interaction generates new information, strengthening the underlying model and improving future care.

Respiratory proved the model. Neuro proved it transfers. The platform is what scales.

Large language models like Claude and ChatGPT have demonstrated extraordinary capabilities and will play an important role in healthcare. But they are fundamentally trained on text. They learn from what has already been written, documented, and observed.

Many healthcare AI companies are built on that same foundation. They rely on data generated by someone else's devices, someone else's care models, or someone else's patients.

Meet Aidah.

Aidah is different because it is trained on what people do.

At the center of Aidah is what we call the Living Patient Model: a continuously evolving understanding of an individual built from physiological signals, clinical context, behavioral patterns, interventions, and outcomes. Rather than relying on population averages, Aidah learns what is normal for a specific person, recognizes when something changes, and helps determine which interventions are most likely to help.

This is what makes Aidah a Physical AI platform. Its intelligence is grounded in the real world. Every signal adds context. Every intervention provides feedback. Every outcome improves understanding.

Most importantly, we own the entire loop.

We build the sensing technologies that capture the signals. We deliver the therapist-guided care that generates interventions. We own the outcomes data that closes the loop. Aidah sits at the center, learning from all three. That creates an advantage that compounds with every new member and every new disease category we enter.

Respiratory was our first application. Neuro was our second. Aidah is the intelligence layer that allows the platform to expand far beyond either one.

With 26 patents issued and pending, combined with a data advantage, we've built a moat that compounds exponentially.

In HCO Respiratory, we sell to payers, who bring us their population of people who need help avoiding ER visits and hospitalizations. Our current contracts are structured as a per-engaged-member-per-month fee with quality bonuses, and we are now moving to value-based contracts as they generate more revenue. We are now in evaluation for opportunities that could generate $25M in revenue. In Neuro, we operate fee-for-service.

HCO Neuro is on track to reach $500K monthly recurring revenue by Q4 2026, bringing the combined entity to cash-flow positive by Q2 2027. Every payer contract that closes between now and then is upside on top of that.

This is not a company that exits once. HCO's model is to incubate each disease vertical to a monetized ARR threshold, then spin it off as an independent company. HCO retains 100% equity at inception. Each entity raises its own capital. Investors in this round own a stake in all four verticals: Respiratory, Neuro, ReSpeak AI, and Cardiology, with exit comparables ranging from $0.6B to $4B in adjacent categories. HCO enters each one with stronger clinical proof and more contracted distribution than any comparable company had at equivalent stage.

Safar Partners is leading this round, as they have led every round of capital HCO has raised since they first invested. Cranberry Capital, our first institutional investor, has maintained their pro rata. When your earliest investors keep writing checks, it means something.

This round gets HCO to cash-flow positive. Not on the strength of projections alone, but because HCO Neuro reaches $500K MRR by Q4 2026 on current trajectory, and that single milestone brings the combined entity there. The downside is cash-flow positivity. Everything else in the pipeline is upside.

The terms are straightforward. This is a SAFE note at a $45M pre-money cap with a 20% discount to the next priced round. $1.5M is committed. $3M remains.

If you invested in our Reg CF campaign, thank you. You helped us build what you are looking at now. This is your chance to go further, on the same terms as our lead VC.

If you are new to HCO, the hardest part is done. What remains is scale.

Reach out directly: [email protected]